In a prospective, randomized, multicenter study, the efficacy and safety of cefoperazone and the combination ampicillin-tobramycin as initial therapy for patients with severe acute biliary tract infections were compared. Of 77 patients initially entered in the study, definite severe biliary tract infection was confirmed in 67. Sixty-four patients completed treatment. At the end of treatment, 35 of 36 (97%) patients given cefoperazone and 23 of 28 (82%) given ampicillin-tobramycin were cured of their infection (P = 0.07). Pathogens were recovered from the bile in 32 patients; microbiological cures were observed in 18 of 19 (94%) patients receiving cefoperazone and 8 of 13 (62%) receiving ampicillin-tobramycin (P = 0.03). Thirteen patients had septicemia. None (0%) of the eight septicemic patients from the cefoperazone group, but two of five (40%) from the ampicillin-tobramycin group, were clinical failures. Of the isolated pathogens, 51% were resistant to ampicillin, while the resistance rate was 4% for tobramycin and 1% for cefoperazone (P < 0.001). Biliary concentrations of cefoperazone were maintained at high levels-236 ± 87
The ideal drug for the treatment of biliary tract infection should have excellent in vitro activity against potential biliary pathogens and should easily penetrate and concentrate within the biliary tree (9, 15) . Cefoperazone is a broad-spectrum cephalosporin which is active in vitro against most aerobic gram-positive bacteria except enterococci and most aerobic gram-negative bacilli including Pseudomonas aeruginosa (17) . It has little activity against anaerobes of Bacteroides fragilis groups. Moreover, cefoperazone, a cephalosporin which contains a methylthio tetrazole group, is excreted in large part in the bile where it can achieve concentrations of more than 6,000 ug/nml (6, 23, 24, 28) . The unique biliary pharmacokinetics of cefoperazone combined with its excellent in vitro activity against most commonly isolated biliary pathogens led us to undertake an open, prospective, randomized, multicenter comparative study to evaluate the efficacy and safety of cefoperazone compared with that of the combination of ampicillin and tobramycin when used for initial therapy of patients with severe acute biliary tract infection.
(This study was presented at the 13th International Congress of Chemotherapy, Vienna, Austria, 1983.) MATERIALS AND METHODS Adult males or females between the ages of 18 and 90 years with severe acute infections of the biliary tract who were hospitalized in seven different Canadian centers were eligible for the study. Fifteen of the patients were more than 75 years old. For a patient to be eligible, the diagnosis had to be confirmed within 5 days of admission by either biliary tract pathology in patients undergoing surgery or, in patients * Corresponding author. who did not undergo surgery, by (i) evidence of biliary tract obstruction by invasive or noninvasive techniques, e.g. ultrasonography, intravenous cholangiography, endoscopic retrograde cholangiography, percutaneous transhepatic cholangiography, hepatobiliary imaging with technetium 99m-labeled dimethyl acetanilide iminodiacetic acid, or computed axial tomography scan; (ii) one or more of the following signs: right upper quadrant pain or tenderness, hyperbilirubinemia, palpable gallbladder; and (iii) one or more of the following: pyrexia, chills, leukocytosis of >12,000/mm3, and/or septicemia. To be defined as suffering from cholangitis, patients had to present with the triad of Charcot: srinking fever with chills, jaundice, and pain in the right upper quadrant. Furthermore, obstruction and inflammation of bile ducts had to be confirmed at surgery.
Reasons for exclusion included patients who were terminally ill or those whose condition precluded evaluation of a therapeutic response, pregnant or nursing women, those with a known or suspected allergy to the penicillin, cephalosporin, or aminoglycoside groups of antibiotics, patients who had been receiving an antibiotic within the preceding 4 days or who required the use of other antibiotic therapy for infections outside the biliary tract, subjects who had an infection outside the biliary tract, patients with significant renal impairment (serum creatinine, >2.5 mg/dl) or with hematological dysfunction (hemoglobin, <9.0 g/dl; leukocyte count, <3,000/mm3; platelets, <75,000/mm3). Tables 4 and 5 .
In Table 2 , the interaction of medical and surgical treatment versus the effect of the two drug regimens on the (7) a Two of these cholecystectomies were done after cessation of antibiotics.
b Four of these cholecystectomies were done after cessation of antibiotics.
outcome was evaluated by a log linear model (8, 34) . The overall outcome was analyzed by the likelihood ratio chisquare test (G2). In Table 3 , the comparison of the three drugs for resistance of bacteria was done by using row-by-column contingency tables with G2 test values.
RESULTS
Patient population. Seventy-seven subjects (39 randomly assigned to receive cefoperazone and 38 to receive ampicillin-tobramycin) were initially included in the study. Eight patients receiving ampicillin-tobramycin and two receiving cefoperazone were excluded because the diagnosis was not subsequently confirmed. Sixty-seven patients could be analyzed; 37 with a mean age of 64 years received cefoperazone therapy, and 30 with a mean age of 63 years received the combination ampicillin-tobramycin. The distribution of age, sex, weight, number of underlying diseases, and duration of illness was similar in both groups. A total of 73% and 63% of the patients receiving either cefoperazone or the combination therapy, respectively, were experiencing their first biliary tract infection. The mean duration of illness before diagnosis was 4.9 and 3.7 days in the cefoperazone and ampicillin-tobramycin groups, respectively. A total of 78% and 68% of patients receiving cefoperazone or ampicillintobramycin, respectively, underwent surgery. Some patients (24 for the cefoperazone group and 17 for the ampicillintobramycin group) received antibiotics for 0 to 2 days before they underwent surgery, while 4 and 2 patients from each group, respectively, began to receive antibiotics 24 to 48 h after surgery. The types of biliary tract infections and surgical interventions, complications, and associated diseases are shown in Table 1 . There was no significant difference in the types of pathology, complications, interventions, and associated diseases observed in the two groups. The mean duration of therapy (7.2 days for cefoperazone and 6.8 days for ampicillin-tobramycin) was similar in both arms of the study. In vitro testing of 27 initial isolates from the bile of cefoperazone-treated patients demonstrated that all were susceptible to cefoperazone (Table 3) . A total of 12 of 23 (52%) initial isolates from the group receiving combination treatment were susceptible to ampicillin, and 22 of 23 (96%) were susceptible to tobramycin. Pathogens isolated from blood were also highly resistant to ampicillin (57%) (P < 0.001), while 0 and 12% of these bacteria were resistant to cefoperazone and tobramycin, respectively. The overall susceptibility of all pathogens isolated during the study is also shown in Table 3 . Similar patterns of susceptibility were observed. At total of 26% of E. coli were resistant to ampicillin. As shown in Table 4 , 18 of 19 (94%) microbiologically evaluable cefoperazone-treated subjects were assessed as having microbiological cures, while 8 of the 13 (62%) ampicillin-tobramycin-treated patients were considered to have microbiological cures (P = 0.03). The bacteriological outcome was similar whether patients had multiple pathogens or a single pathogen. In the cefoperazone-treated patients, one patient had a microbiological failure owing to persistent infection with E. coli and colonization with Klebsiella oxytoca and enterococcus. In another patient, Salmonella species was isolated from bile a few days after the initial bile culture had shown E. coli. We believe that the Salmonella species was missed on the initial culture and that it was a mixed,infection with E. coli and Salmonella species.
In three of the patients receiving ampicillin-tobramycin, treatment failed to eradicate the original pathogens from the bile (two E. coli, one P. aeruginosa), and in one case B. fragilis was isolated in the blood of the patient on day 3 of therapy. On day 4, the patient was switched to cefoperazone and did well. The fifth patient with microbiological failure had ampicillin-resistant Klebsiella pneumoniae isolated from blood and, although sensitive to tobramycin and cefoperazone, was switched to cefamandole. Two patients were colonized with Serratia spp. Most pathogens involved in the failures were susceptible to either cefoperazone or tobramycin but resistant to ampicillin. We did not find any difference in the ampicillin plus tobramycin or -cefoperazone group in the type of biliary pathology or underlying diseases.
Three of the ampicillin-tobramycin-treated patients having microbiological failure were septicemic, and two of these had clinical failures. None of the septicemic patients receiving cefoperazone had clinical failures, but one had a microbiological failure. Most patients with septicemia were initially obstructed, and the incidence of septicemia in obstructed biliary tract disease was not significantly different in both groups.
Minor drug-related side effects including rash, diarrhea, and phlebitis occurred in seven cefoperazone-and five ampicillin-tobramycin-treated patients. No significant laboratory abnormality was detected which necessitated discontinuation of treatment. In one apparently normal patient with common bile duct obstruction treated with cefoperazone, a prothrombin time prolongation was observed during therapy without any adverse consequence. It was corrected with vitamin K administration at the end of therapy. An increase in serum creatinine was noted in three patients receiving ampicillin-tobramycin, while it was observed in only one patient, receiving cefoperazone. The creatinine rises were, respectively, 1.3, 1.3, and 1.99 mg. The level returned to normal as treatment with tobramnycin ceased.
In the 10 patients in whom levels of cefoperazone were evaluated, the respective serum levels (micrograms per milliliter standard deviation) at 1.5, 4, 8, and 12 h were 157 ± 16, 84 + 9, 35 3, and 26 ± 4. Biliary levels peaked at 464 ± 151 ,ug/ml between 2 and 4 h after the dose and were maintained at high levels (236 87 ,ug/ml) up to 12 h after administration. Of these 10 patients, 4 had severe obstruction'of their biliary tracts. The levels of cefoperazone were still several times above the MIC for the pathogens involved ( Table 5 ). As observed in two patients in whom biliary levels were determined again 3 days after the obstruction was released, the levels increased considerably. Levels in gallbladder walls were lower than those in the bile.
DISCUSSION
Despite the fact that severe biliary infection is a common clinical problem associated with high morbidity and mortality, there is no standardized approach to the therapy of these infections. The proper choice of a therapeutic regimen should be based on the severity of the disease process, the suspected biliary pathogens, and the in vitro activity and biliary pharmacology of potentially effective antimicrobial agents.
There is a very limited number of prospective randomized clinical trials on the proper choice of antimicrobial agents in the treatment of biliary tract infections (7, 14, 22 (7, 9, 14) , but the use of antibiotics in patients with uncomplicated cholecystitis is still a matter of controversy. In fact, unless cholecystitis occurs in an older patient or is associated with cystic or common bile duct obstruction (1, 10, 36) , the incidence of active infection is less than 50% (11, 32) .
In the present study, criteria for inclusion were very strict. Only patients with severe biliary tract infection could be included. A total of 25% of our patients had severe cholangitis, 40% had either cystic or common bile duct obstruction, 20% developed septicemia, and 17% had severe necrotizing cholecystitis at the time of operation.
The results of our evaluation suggest that cefoperazone is more effective than ampicillin plus tobramycin in the acute phase of biliary tract infection. Of 36 cefoperazone-treated patients and 28 ampicillin-tobramycin-treated patients, 35 (97%) and 23 (82%), respectively, were cured of their infections (P = 0.07). Although the number of evaluable patients was smaller in the ampicillin-tobramycin arm of the study, none of the base-line characteristics of the two groups differed statistically. Measures of association for two-way frequency tables and log linear model were done to assess the influence of surgery, the severity of infection, the presence of underlying disease, or the presence of biliary obstruction on the outcome of therapy. After these factors were taken into account, treatment with cefoperazone was still associated with a higher response rate. In a prospective randomized study in which 119 patients were given either ampicillin or cefamandole as prophylaxis or treatment of biliary tract infections, Levi et al. (22) did not find any difference in the outcome of therapy. Havig and Hertzberg (14) , comparing ampicillin, chloramphenicol, and penicillinchloramphenicol in 77 patients with cholecystitis, and De Ritis and Scioli (7), comparing ampicillin and hetacillin in 38 patients with either acute or chronic cholecystitis or cholangitis, observed that all these drug regimens were equally effective. In most of these studies, the cure rate varied between 80 and 100%, but in these four randomized trials, the patients studied were not as severely ill as in the present study and the criteria for diagnosis and outcome were poorly defined. In the few noncomparative studies in which either ampicillin or gentamicin was used alone for the treatment of biliary diseases, the cure rate varied between 80 and 88%, but these studies involved small numbers of cases which were not well defined (12, 13, 41) . In Japan, noncomparative trials with cefoperazone have revealed an overall success rate of 78% in 116 patients suffering from biliary tract infections (24) . The efficacy in 50 cases of cholecystitis was 84%, in 33 patients with cholangitis it was 67%, and in 27 cases identified as biliary tract infections it was 82% (24) . Six patients had a liver abscess, and the cure rate was 67% (11). Cristiano et al. (6) , in a smaller study involving 25 patients, showed that 21 patients (84%) recovered completely with cefoperazone. In the four patients who failed to recover (16%), one was pancytopenic, one had diabetis mellitus, one had multiple liver abscesses, and the other had gallbladder cancer (6) .
In addition to the excellent clinical response observed in our study, very few microbiological failures were observed in the cefoperazone group. While cefoperazone could not eradicate the pathogens in only 6% of the patients, ampicillin-tobramycin failed to sterilize the bile in 36% of patients (P = 0.03). The incidence of positive cultures and the bacterial species recovered from blood and bile were identical to those reported by others (5) . The limited eradication rate with ampicillin-tobramycin can most likely be explained by the fact that 51% of the bacteria isolated from the biliary tree were resistant to ampicillin. Although most pathogens (96%) were susceptible to tobramycin, the poor penetration of aminoglycosides into the bile may explain the persistence of pathogens within the bile (19, 31, 39) . In contrast, only 1% of the pathogens were resistant to cefoperazone. The three Pseudomonas spp. tested were also susceptible to cefoperazone. Of crucial importance was the finding that two of the five patients who had septicemia and were treated with ampicillin-tobramycin failed to recover on this regimen, while all eight septicemic patients treated with cefoperazone were cured of their disease.
The observed increase in clinical and bacteriological cure rate with cefoperazone may also be attributed to its unique biliary pharmacology. In contrast to other cephalosporins which may reach maximum biliary concentrations of less than 364 ,ug/ml after a 1-or 2-g dose (33) , cefoperazone may reach maximal biliary levels of more than 6,000 jig/ml in the common duct bile and 680 ,ug/ml in gallbladder bile after a 2-g dose (20, 23) . Maximum cefoperazone concentrations of 348 ,ug/g of gallbladder wall have been observed after a 2-g dose (6) . In our present study, the mean peak biliary level was 464 ,ugIml. All patients including those with severe obstruction had levels above 30 ,ug/ml in the bile and 3.5 ,ug/ g in the gallbladder. These levels are above the MIC of cefoperazone for most biliary pathogens. After a 500-mg dose of ampicillin, Mortimer et al. (26) have observed levels of 22 pug/ml in the bile from the common bile duct. Maximum levels of 273 ,ug/ml were observed by Ayliffe and Davis (2) . Aminoglycosides penetrate poorly into the bile.
Maximum biliary levels of 3.0 jxg/ml were observed after high doses of gentamicin (25, 39) . The extremely high biliary levels of cefoperazone, coupled with its excellent in vitro activity, which resulted in a very high concentration over MIC ratio within the infected biliary tree, have certainly played a determinant role in the outcome of therapy in these patients with severe biliary tract infections and were probably responsible for the elimination of the biliary pathogens in 18 of the 19 patients. The limited in vitro activity of ampicillin coupled with the poor penetration of aminoglycosides into the bile may have been responsible for the limited clinical and microbiological outcome with the combination. Cefoperazone, which was effective in vitro against P. aeruginosa isolated in this study, sterilized the bile of two patients harboring this agent. As reported previously, P. aeruginosa was observed exclusively in patients with cancer (1, 5, 10, 36) . Anaerobes were recovered from six patients. With the exception of an episode of B. fragilis septicemia which did not respond to ampicillin-tobramycin, all the other anaerobes were eliminated rapidly from the bile. Of interest, VOL. 32, 1988 
